^
Association details:
| Biomarker: | NRAS mutation + BRAF mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells
Published date:
06/30/2020
Excerpt:
The present study tested the combination therapy of metformin and trametinib by monitoring the alterations of regulatory effector proteins of cell signaling pathways and the effect of the combination on cell viability in NCI-H2087 NSCLC cells with NRAS and BRAF mutations... The combination therapy synergistically decreased cell viability in treatment with low doses of two drugs...
Secondary therapy:
metformin
DOI:
10.12717/DR.2020.24.2.113
